Insulet Corporation  

(Public, NASDAQ:PODD)   Watch this stock  
Find more results for podd
29.09
+0.53 (1.86%)
After Hours: 29.09 0.00 (0.00%)
May 23, 4:32PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 28.33 - 29.62
52 week 23.94 - 40.21
Open 28.60
Vol / Avg. 0.00/717,697.00
Mkt cap 1.68B
P/E     -
Div/yield     -
EPS -1.27
Shares 57.16M
Beta 1.33
Inst. own 109%
Aug 10, 2016
Q2 2016 Insulet Corp Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
May 12, 2016
Insulet Corp Annual Shareholders Meeting (Estimated)
May 11, 2016
Insulet Corp Annual Shareholders Meeting
Apr 28, 2016
Q1 2016 Insulet Corp Earnings Call
Apr 28, 2016
Q1 2016 Insulet Corp Earnings Release
Mar 7, 2016
Insulet Corp at Raymond James Institutional Investors Conference
Feb 25, 2016
Q4 2015 Insulet Corp Earnings Call - Webcast
Feb 25, 2016
Q4 2015 Insulet Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -13.16% -22.68%
Operating margin -9.48% -18.74%
EBITD margin - -13.86%
Return on average assets -16.18% -25.69%
Return on average equity -141.85% -124.74%
Employees 647 -
CDP Score - -

Address

600 Technology Park Dr Ste 200
BILLERICA, MA 01821-4126
United States - Map
+1-978-6007000 (Phone)
+1-978-6000120 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The OmniPod System consists of the OmniPod, a small, self-adhesive disposable tubeless OmniPod device, which is worn on the body for approximately three days at a time and its wireless handheld Personal Diabetes Manager (PDM). The Company purchases OmniPods pursuant to its agreement with Flextronics. It also partners with pharmaceutical and biotechnology companies to tailor the OmniPod technology platform for the delivery of subcutaneous drugs across multiple therapeutic areas. It sells the OmniPod System and other diabetes management supplies in the United States through direct sales to customers or through its distribution partners. The Company purchases OmniPods pursuant to its agreement with Flextronics. The OmniPod System is available in Europe, Canada and Israel.

Officers and directors

Michael L. Levitz Chief Financial Officer
Age: 41
Bio & Compensation  - Reuters
Daniel J. Levangie President - Insulet Drug Delivery
Age: 64
Bio & Compensation  - Reuters
Shacey Petrovic President -- Insulet Diabetes Products
Age: 41
Bio & Compensation  - Reuters
Bradley Thomas CFA Executive Vice President - Human Resources & Organizational Development
Age: 57
Bio & Compensation  - Reuters
Mark Licari Vice President - Global Manufacturing and Operations
Bio & Compensation  - Reuters
David Colleran J.D. Vice President, General Counsel
Bio & Compensation  - Reuters
Patrick J. Sullivan President, Chief Executive Officer, Director
Age: 64
Bio & Compensation  - Reuters
John A. Fallon M.D. Lead Independent Director
Age: 68
Bio & Compensation  - Reuters
Jessica Hopfield Director
Bio & Compensation  - Reuters
Charles T. Liamos Director
Age: 55
Bio & Compensation  - Reuters